AUG 11, 2026 · PHASE 3 TRIAL
Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation
ClinicalTrials.gov
This is a clinical trial registry record describing a planned or ongoing Phase 3 study with no results posted; efficacy and safety data are not yet available in this source.
Reported
Planned enrollment453
Primary outcome measureProgression-Free Survival (PFS) as Per Blin…
PFS follow-up durationup to approximately 143 weeks